Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kura Oncology reports Q4 loss, highlights ziftomenib's AML potential

Kura Oncology's Q4 2022 performance reflects increased R&D expenses and a net loss, offset by a strong cash position supporting operations.
The company's focus on ziftomenib's positive trial data, combination studies, and patient-centric strategies positions it for future growth.
Challenges lie in managing treatment complexities, strategic resource allocation, and balancing commercial value with patient benefit.
Opportunities include upcoming milestones, exploration of combination therapies, and regulatory advancements for ziftomenib.

Kura Oncology sees positive results with ziftomenib in Q1

Kura Oncology's Q1 2023 earnings call highlighted the promising performance of ziftomenib in AML patients, supported by strong Phase 1 trial data and strategic plans for combination studies.
While facing challenges in competitive differentiation and trial execution, the company's financial stability and focus on methodical drug development underscore its long-term potential.
Opportunities lie in achieving key milestones, exploring new therapeutic applications, and leveraging a competitive edge in the menin inhibitor space for future growth and success.

Kura Oncology reports Q2 loss, sees growth in clinical trials

Kura Oncology's Q2 2023 performance reflects increased expenses but promising clinical outcomes, with strong enrollment and positive data in key trials.
Strategic strengths lie in combination studies, diversified indications, and positive trial results, positioning the company for future growth and market expansion.
Challenges include resource constraints, research prioritization, and evolving resistance issues, necessitating adaptive strategies and efficient resource management.
Opportunities for Kura Oncology include collaborations, out-licensing, and program expansions, offering avenues for operational efficiency and revenue growth.

Kura Oncology's ziftomenib shows promise in acute leukemias, financials stable

Kura Oncology's Q3 performance reflects increased expenses but maintains a strong financial position.
The company's lead drug candidate, ziftomenib, shows promise in acute leukemias, with positive response rates.
Strategic strengths include progress with menin inhibitors, successful combination approaches, and clinical collaborations.
Challenges lie in meeting enrollment timelines, addressing efficacy questions, and balancing program investments.

Kura Oncology reports promising clinical data and financial stability

Kura Oncology's Q4 2023 performance showcased positive clinical data and financial stability, positioning the company well for future growth.
While challenges in data interpretation and differentiation exist, opportunities in milestone achievements and patient-focused therapies are on the horizon.
The company's strategic focus on early therapy lines and combinability of menin inhibitors highlight its strengths in the competitive market landscape.

Kura Oncology reports promising results for ziftomenib in Q1

Kura Oncology's Q1 2024 performance reflects increased R&D expenses and promising results for ziftomenib.
Strengths lie in FDA support, encouraging safety profiles, and ongoing combo dose escalation trials.
Challenges include patient characteristics impacting therapy duration and strategic resource allocation.
Opportunities include upcoming milestones, solid tumor data disclosure, and competitor monitoring for market insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Ziftomenib, Kura's lead candidate, shows promising results in AML treatment, with a 35% complete remission rate, and could address up to 50% of AML patients. The stock is upgraded to Strong Buy due to its deep value, strong pipeline performance, and potential for substantial upside if FDA approval and commercialization go according to plan.

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH

Kura Oncology to Host Virtual Investor Event on December 9, 2024

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Kura Oncology slammed the door on its takeover narrative Thursday, inking a deal for its leukemia drug. Kura stock crashed.

Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%

Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and Accounting Dr. Mollie Leoni - Executive Vice President, Clinical Development Conference Call Participants Li Watsek - Cantor Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Charles Zhu - LifeSci Capital Phil Nadeau - TD Cowen Peter Lawson - Barclays Justin Zelin - BTIG Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call.

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (Nasdaq: KURA) and has served as chairman of its Board of Directors since it was founded in 2014. “We are delighted to hav.

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models –

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

– New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – – New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics –

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled “Ziftomenib in relapsed/refractory acute myeloid leukaemia (KOMET-001): results from an open-label, multi-cohort, phase 1a/1b trial,” is now available on The Lancet Oncology website and in the Scientific Manuscripts section on Kura's website.

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership.

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Pete De Spain - Head, IR Troy Wilson - President and CEO Thomas Doyle - SVP of Finance and Accounting Conference Call Participants Li Watsek - Cantor Fitzgerald Jonathan Chang - Leerink Partners Cameron Bozdog - Bank of America Roger Song - Jefferies Brad Canino - Stifel Phil Nadeau - TD Cowen Alex Bouilloux - Barclays Justin Zelin - BTIG George Farmer - Scotiabank Operator Good day, and welcome to the Q2 2024 Kura Oncology Conference Call. [Operator Instructions] Please note this event is being recorded.

Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript

– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses –

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2024 financial results after the close of U.S. financial markets on Thursday, August 8, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2024 Financial Results

Endava plc - ADR

ProPetro Hld

The first lesson in investing is that returns are not guaranteed — especially in stocks. Companies constantly fluctuate in value as the wheel of the stock market turns, and daily trades come in by the millions.

Don't Miss Out: 3 Stocks Poised for a 10X Surge

SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,700 shares of common stock to eight (8) new employees under the Company's 2023 Inducement Option Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disrupt the cycle of poverty and inequity throughout its communities, and Kura Oncology are continuing their partnership to support the San Diego community. Kura Oncology is contributing $100,000 through Life Science Cares' Basic Needs portfolio to support local nonprofit, Mama's Kitchen, with meeting.

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Jefferies Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on June 5, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event.

Kura Oncology to Participate in Jefferies Global Healthcare Conference

– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company's menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The Company expects to report topline data from the trial in early 2025.

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Hims & Hers Health

Growth stocks are experiencing a multi-decade bull run at the moment. Kura Oncology and Hims & Hers are two red-hot growth stocks worth checking out right now.

News for Kura Oncology Stock (KURA)